ReutersReuters

Patritumab Deruxtecan Biologics License Application For Patients With Previously Treated Locally Advanced Or Metastatic Egfr-Mutated Non-Small Cell Lung Cancer Voluntarily Withdrawn

RefinitivThời gian đọc: dưới 1 phút
  • PATRITUMAB DERUXTECAN BIOLOGICS LICENSE APPLICATION FOR PATIENTS WITH PREVIOUSLY TREATED LOCALLY ADVANCED OR METASTATIC EGFR-MUTATED NON-SMALL CELL LUNG CANCER VOLUNTARILY WITHDRAWN

Đăng nhập hoặc tạo tài khoản miễn phí trọn đời để đọc tin tức này